MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology

Gaithersburg, Maryland – 23 October 2019 – MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, announces two presentations at the 5th Annual Cell & Gene Therapy Congress (ACGTC) taking place 29-30 October in London, UK, which showcase the Company’s cell therapy technology.

Details of the presentations are as follows:

Presenter: Michael O’Dwyer, Founder and CSO, ONK Therapeutics

Title: The rationale for the development of CAR-NK cells for the treatment of Multiple Myeloma

Date: Tuesday, 29 October, 9:30 a.m. – 10:00 a.m. GMT

Location: Bourgogne Conference Room

The presentation will focus on the background to treatment of multiple myeloma with current unmet medical needs and experience to date with CAR-T cells in myeloma. It will also include an introduction to NK cells and their function in myeloma and the rationale for development of CAR-NK in myeloma. Technology utilized was licensed from MaxCyte.

Presenter: Chris Mann, Director, Field Applications Scientists Team, MaxCyte

Title: Aligning Gene Editing & Cell Line Engineering to Improve Biotherapeutic Discovery, Efficacy and Bioproduction

Date: Wednesday, 30 October, 12:30 p.m. – 1:00 p.m. GMT

Location: Bourgogne Conference Room

The presentation will focus on lessons and engineering approaches from cell therapy and how they can be harnessed to rapidly generate custom CHO cell lines using gene editing, including engineering of CHO manufacturing cell lines and generation of CHO cell lines with integration landing pad for simplified engineering. The presentation will also include a case study entitled: “Improving HIV vaccine immunogenicity and manufacturing using CRISPR-mediated creation of CHO MGAT- cell line and rapid generation of stable gp120-expressing cell lines”.

The conference takes place 29-30 October at Novotel London West Hotel, London, United Kingdom. For more information, please visit: https://www.oxfordglobal.co.uk/cell-series-uk/genetherapy/

Doug Doerfler, CEO of MaxCyte, said: “We are a life science business committed to driving the next generation of cell-based therapies, and our technology has become the go-to for cell-engineering. The Company is experiencing exciting progress, with new partnerships and expanded collaborations demonstrating an increasing interest in MaxCyte among leading gene-editing and immuno-oncology companies. We are very pleased to be presenting at the ACGTC on the potential of our advanced therapy technologies.”

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six announced commercial licenses with aggregate potential milestones of more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

For further information, please contact: